Back to News & Media

Press Releases

February 27, 2025

Frontier Medicines to Participate in Two Upcoming March Investor Conferences

January 9, 2025

Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential

January 8, 2025

Frontier Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference

July 23, 2024

Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription Factor

June 25, 2024

Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C Extension

April 9, 2024

Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting

March 21, 2024

Frontier Medicines to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2024